Zobrazeno 1 - 10
of 34
pro vyhledávání: '"I L Popova"'
Autor:
O I Kit, L Y Vladimirova, N A Abramova, A E Storozhakova, I L Popova, N M Tikhanovskaya, A A Lyaynova, L A Ryadinskaya
Publikováno v:
Современная онкология, Vol 19, Iss 2, Pp 42-46 (2017)
The data of the efficacy and safety regorafenib in the treatment of 7 patients with metastatic colorectal cancer (mCRC) refractory to treatment with cytostatics and monoclonal antibodies - blockers EGFR and VEGF were analyzed. The maximum anti-tumor
Externí odkaz:
https://doaj.org/article/e022525b6858401aaef3c15fabbf6fb3
Autor:
L V Bolotina, L V Manziuk, V A Gorbunova, E I Kovalenko, G Z Mukhametshina, A I Khasanova, L Yu Vladimirova, I S Mitashok, E P Prokofyeva, I V Evstigneeva, I I Andreyashkina, N A Abramova, I L Popova, E V Karabina, A A Teterich, E A Gaysina, V A Chubenko, S V Limareva, N M Tikhanovskaya, A E Storozhakova, N Yu Samaneva, Ya V Svetitskaya, T A Snezhko, E A Kalabanova
Publikováno v:
Современная онкология, Vol 18, Iss 3, Pp 27-32 (2016)
The article shows the experience of eribulin application in actual clinical practice in Oncology institutions of the Russian Federation concerning metastatic breast cancer. We have analyzed the efficacy of the drug in case of different subtypes of th
Externí odkaz:
https://doaj.org/article/02544f99d49748aabf8218f99df2b907
Autor:
A. A. Lyanova, L. Yu. Vladimirova, E. P. Ulyanova, N. A. Abramova, A. E. Storozhakova, I. L. Popova, N. M. Tikhanovskaya, M. A. Teplyakova, L. A. Ryadinskaya, I. A. Udalenkova, E. A. Kalabanova, S. N. Kabanov
Publikováno v:
Южно-Российский онкологический журнал, Vol 3, Iss 4, Pp 40-48 (2022)
Purpose of the study. An analysis of changes in the expression of the VEGF neoangiogenic factor in the tumor tissue of patients with squamous cell carcinoma of the oral mucosa receiving targeted therapy with cetuximab and chemotherapy.Patients and me
Externí odkaz:
https://doaj.org/article/aaad8131f37d45919c047248caac54d3
Autor:
L. Yu. Vladimirova, E. M. Frantsiyants, N. A. Abramova, K. A. Novoselova, V. S. Myagkova, O. V. Katelnitskaya, A. E. Storozhakova, I. L. Popova, S. N. Kabanov, N. M. Tikhanovskaya, E. A. Kalabanova, L. A. Ryadinskaya, A. A. Lyanova, M. A. Teplyakova, V. R. Zakharchenko, N. K. Guskova
Publikováno v:
Issledovaniâ i Praktika v Medicine, Vol 9, Iss 3, Pp 25-38 (2022)
Purpose of the study. An analysis of parameters of the blood coagulation system in breast cancer patients after coronavirus disease.Materials and methods. 50 breast cancer patients were divided into groups: the main group included 30 patients after c
Externí odkaz:
https://doaj.org/article/11865fec689245e7beb91d9a5389d4d9
Autor:
A. A. Lianova, L. Yu. Vladimirova, N. A. Abramova, M. A. Teplyakova, I. L. Popova, N. M. Tikhanovskaya, A. E. Storozhakova, L. A. Ryadinskaya, I. A. Udalenkova, E. A. Kalabanova, D. Trifanov
Publikováno v:
Medical alphabet. :28-34
Autor:
L. Yu. Vladimirova, M. A. Teplyakova, I. L. Popova, N. A. Abramova, N. M. Tikhanovskaya, A. A. Lianova, A. E. Storozhakova, L. A. Ryadinskaya, S. N. Kabanov, E. A. Kalabanova, I. A. Udalenkova, D. Trifanov
Publikováno v:
Medical alphabet. :35-40
Although melanoma is one of the most immunogenic tumors, it has an ability to evade anti-tumor immune responses by exploiting tolerance mechanisms. The most extensively studied checkpoints represent cytotoxic T lymphocyte-associated protein‑4 (CTLA
Autor:
L. Yu. Vladimirova, N. A. Abramova, A. A. Lyanova, A. E. Storozhakova, I. L. Popova, M. A. Teplyakova, N. M. Tikhanovskaya, L. A. Ryadinskaya, E. A. Kalabanova, S. N. Kabanov, I. A. Udalenkova
Publikováno v:
Meditsinskiy sovet = Medical Council. :117-125
Introduction. Erythropoietin (EPO) application is a pathogenetic method for anemia correction in cancer patients.The purpose of study. Clinical evaluation of the efficacy and safety of Eralfon® (epoetin alpha) in treatment for anemia in patients wit
Autor:
L. Yu. Vladimirova, I. L. Popova, N. A. Abramova, M. A. Teplyakova, N. M. Tikhanovskaya, A. A. Lianova, A. E. Storozhakova, L. A. Ryadinskaya, S. N. Kabanov, E. A. Kalabanova
Publikováno v:
Meditsinskiy sovet = Medical Council. :186-192
The development of a new area of antitumor drug therapy, immunotherapy using immune checkpoint inhibitors targeting PD-1/PD-L1, has significantly changed approaches to the treatment of advanced non-small cell lung cancer (NSCLC). Many clinical trials
Autor:
M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyaeva, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, L. V. Bolotina, R. V. Orlova, F. V. Moiseenko, G. Z. Mukhametshina, A. I. Khasanova, A. V. Belonogov, Kh. S. Musaeva, O. Yu. Novikova, I. Yu. Stradaeva, I. L. Popova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, E. S. Kuzmina, E. V. Karabina, O. V. Nekrasova, O. V. Sekhina, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. R. Malina, M. A. Lyadova, A. A. Tryakin, S. A. Tyulandin
Publikováno v:
Pelvic Surgery and Oncology. 11:11-17
Objective: to compare the efficacy and toxicity of aflibercept and bevacizumab in combination with fOLfIRI in secondline therapy for patients with metastatic colon cancer.Materials and methods. we performed a retrospective analysis of data on patient
Autor:
L. Yu. Vladimirova, A. Eh. Storozhakova, I. L. Popova, S. N. Kabanov, N. A. Abramova, M. A. Teplyakova, N. M. Tikhanovskaya, K. A. Novoselova, A. A. Lyanova, L. A. Ryadinskaya, V. S. Myagkova, F. V. Alieva, E. A. Kalabanova, Ya. V. Svetitskaya, N. Yu. Samaneva, A. V. Tishina
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 64-74 (2021)
The development of a new direction in anticancer medical therapy – the use of immune checkpoint inhibitors targeting PD-1/ PD-L1 and CTLA-4 – has significantly changed the approach to tumor treatment in the last few years. The PD1 blocker nivolum